Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
Travere Therapeutics Inc (TVTX) is a biopharmaceutical innovator developing therapies for rare kidney, liver, and metabolic diseases. This page provides a comprehensive repository of official company announcements, clinical trial updates, and regulatory developments.
Investors and researchers will find curated press releases detailing milestones for pipeline candidates like FILSPARI and sparsentan, along with financial disclosures and partnership announcements. Content is organized to highlight material events including FDA communications, trial phase completions, and strategic collaborations.
All updates are sourced directly from Travere Therapeutics to ensure accuracy. Bookmark this page for efficient tracking of the company’s progress in advancing treatments for IgA nephropathy, FSGS, and other rare conditions.
Travere Therapeutics (NASDAQ: TVTX) announced the grant of inducement equity awards totaling 89,950 shares to eleven new employees on July 10, 2021. This includes stock options for 65,100 shares and restricted stock units (RSUs) covering 24,850 shares, granted outside the 2018 Equity Incentive Plan. The stock options have an exercise price of $14.68 and a 10-year term, vesting over four years. The RSUs also vest over four years. This initiative aims to attract talent critical for advancing its mission in rare disease treatments.
Travere Therapeutics (NASDAQ: TVTX) announced presentations on nonclinical data of sparsentan at the 58th ERA-EDTA Congress, focusing on its renal protective effects in focal segmental glomerulosclerosis (FSGS) mouse models. Key findings include analyses revealing significant treatment effects in proteinuria reduction for FSGS and IgA nephropathy. The company is currently conducting pivotal Phase 3 studies for sparsentan, which has shown statistical significance in achieving its interim endpoint of reduced proteinuria, suggesting promising potential for regulatory approval for both conditions.
Travere Therapeutics announced the completion of patient enrollment in the Phase 3 PROTECT Study for sparsentan, targeting IgA nephropathy. This pivotal study aims to assess the drug's safety and efficacy in approximately 380 patients, with topline data for the interim 36-week proteinuria endpoint expected in August 2021. Sparsentan could potentially become a non-immunosuppressant treatment option for this severe kidney disorder, which currently has no approved therapies.
Travere Therapeutics (NASDAQ: TVTX) will present at upcoming virtual investor conferences throughout June 2021. Key events include:
- Jefferies Virtual Healthcare Conference on June 2 at 1:00 p.m. ET
- JMP Securities Life Sciences Conference on June 16 at 11:00 a.m. ET
- BMO Biopharma Day on June 22 at 11:15 a.m. ET
Live webcasts will be available on their website, and archived replays can be accessed for up to 30 days. Travere is dedicated to developing therapies for rare diseases and aims to support patients and families affected by these conditions.
Travere Therapeutics (NASDAQ: TVTX) provided a regulatory update on its sparsentan program for focal segmental glomerulosclerosis (FSGS). Following successful interim results from the Phase 3 DUPLEX Study, the FDA indicated that the data was insufficient for accelerated approval this year. The company remains optimistic about future submissions pending additional data expected in 2022. Meanwhile, initial discussions with the EMA supported a conditional marketing authorization submission planned for late 2021. Results from the confirmatory endpoint are anticipated in 2023.
Travere Therapeutics (TVTX) reported first-quarter 2021 financial results, highlighting net product sales of $47.4 million, slightly down from $47.8 million YoY. The company achieved a significant milestone by completing the interim endpoint in the DUPLEX Study of sparsentan for FSGS and is pursuing accelerated approval from regulators. The PROTECT Study for IgA nephropathy is nearing full enrollment, with topline data expected in Q3 2021. Cash and equivalents stood at $520.9 million as of March 31, 2021. Despite increased R&D and SG&A expenses, the company remains optimistic about future growth.
Travere Therapeutics (NASDAQ: TVTX) announced that CEO Eric Dube, Ph.D., will present at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 5:00 p.m. ET. A live webcast of the presentation will be available on the company's investor relations page and an archived replay will be accessible for 30 days thereafter.
The company is dedicated to addressing the urgent treatment needs of patients with rare diseases and aims to deliver impactful therapies in collaboration with the rare disease community.
Travere Therapeutics (NASDAQ: TVTX) will announce its Q1 2021 financial results on May 6, 2021, after U.S. market close. A conference call is scheduled for the same day at 4:30 p.m. ET, aimed at discussing the results and providing a business update. Interested participants can join via dial-in or a live webcast on Travere's investor relations site. A replay will be accessible from 7:30 p.m. ET on May 6 to 7:30 p.m. ET on May 13.
Travere Therapeutics (TVTX) announced strong performance in its fourth quarter and full year 2020 financial results, with net product sales increasing by 13% year-over-year to $198 million. The company reported a net loss of $121.6 million for Q4 2020, compared to $30.3 million in Q4 2019. Key developments include achieving the interim endpoint in the DUPLEX Study for FSGS and plans to report data from the PROTECT Study for IgAN in Q3 2021. The company’s cash position stands at $361.6 million, boosted by a recent stock offering generating $189 million in proceeds.
Travere Therapeutics (NASDAQ: TVTX) participates in Rare Disease Day 2021, honoring over 400 million individuals worldwide affected by rare diseases. CEO Eric Dube emphasizes their commitment to improving patient outcomes and community access to treatment. The company supports various organizations tackling healthcare inequities and promoting innovation in rare diseases. The National Burden of Rare Disease Study, expected to release economic impact findings on February 25, aims to raise awareness and inform policy changes. Travere will host an internal event on February 26 to celebrate this initiative.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
